Earnings release
Page 1
Veracyte Announces Third Quarter 2025 Financial Results November 4, 2025 Grew total revenue to $131.9 million and testing revenue to $127.8 million, representing increases of 14% and 17% year-over-year, respectively Conference call and webcast today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nov. 4, 2025-- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced financial results for the third quarter ended September 30, 2025. “We delivered another outstanding quarter of testing revenue growth and adjusted EBITDA margin expansion, enabling us to raise both our revenue and profitability guidance,” said Marc Stapley, Veracyte’s chief executive officer. “We continue to advance our mission of transforming cancer care by generating high-quality evidence and clinical insights that reinforce the value of our tests and our market leadership. The strong momentum we have seen this year, combined with our upcoming TrueMRD and Prosigna LDT launches, gives us confidence in delivering durable, long-term growth from our broad portfolio of tests covering the care continuum in multiple indications.” Key Financial Highlights For the three-month period ended September 30, 2025, as compared to the same period in 2024: Increased total revenue by 14% to $131.9 million and testing revenue by 17% to $127.8 million. Increased total volume by 18% to 45,888 tests and testing volume by 19% to 43,679 tests. Grew Decipher revenue by 26% to $82.2 million and Afirma revenue by 7% to $43.2 million. Grew Decipher volume by 26% to approximately 26,700 tests and Afirma volume by 13% to approximately 17,000 tests. Recorded GAAP net income of $19.1 million, or 15% of revenue, including $6.7 million of loss related to the deconsolidation of the SAS entity. Delivered adjusted EBITDA of $39.7 million, or 30% of revenue. Generated $44.8 million of cash from operations to end the quarter with $366.4 million of cash, cash equivalents, and short-term investments as of September 30, 2025. Raised full year revenue guidance to $506 million to $510 million, including raising testing revenue guidance to $484 million to $487 million or 16% year-over-year growth. Key Business Highlights Presented at ASTRO 2025 nine Decipher-focused abstracts, including the first validation data from the BALANCE trial that demonstrated the PAM50 molecular signature predicts hormone therapy benefit in men with recurrent prostate cancer using Decipher GRID. Announced data published online in Cell from the STAMPEDE trial showing that the Decipher Prostate Genomic Classifier predicts chemotherapy benefit in patients with metastatic prostate cancer in an effort to help patients avoid unnecessary toxicity. Launched the Afirma v2 transcriptome to improve the efficiency of the Afirma testing business, while providing a platform for future product launches, such as Prosigna LDT. Supported the presentation of twelve abstracts covering clinical Afirma GSC data and research with Afirma GRID at the 2025 American Thyroid Association Annual Meeting. Completed NIGHTINGALE clinical utility trial enrollment for the Percepta Nasal Swab test. A reconciliation of GAAP to non-GAAP financial measures has been provided in the tables included in this press release. An explanation of these measures is also included below under the heading "Note Regarding Use of Non-GAAP Financial Measures." Third Quarter 2025 Financial Results Total revenue for the third quarter of 2025 was $131.9 million, an increase of 14% compared to $115.9 million reported in the third quarter of 2024. Testing revenue was $127.8 million, an increase of 17% compared to $109.5 million in the third quarter of 2024, driven by growth in our Decipher Prostate and Afirma tests. Product revenue was $3.3 million, an increase of 4% compared to $3.2 million in the third quarter of 2024. Biopharmaceutical and other revenue was $0.8 million, a decrease compared to $3.1 million in the third quarter of 2024 given the restructuring and liquidation proceedings of Veracyte SAS. Total gross margin for the third quarter of 2025 was 69%, compared to 68% in the third quarter of 2024. Non-GAAP gross margin was 73%, compared to 71% in the third quarter of 2024. Operating expenses were $68.3 million for the third quarter of 2025. Non-GAAP operating expenses grew 2% to $58.6 million compared to $57.6 million in the third quarter of 2024. Net income for the third quarter of 2025 was $19.1 million, an improvement of 26% compared to the third quarter of 2024, including a $6.7 million loss from the deconsolidation of the Veracyte SAS entity. Diluted net earnings per common share was $0.24, an improvement of $0.05 compared to the third quarter of 2024. Non-GAAP diluted net earnings per common share was $0.51, an increase of $0.18 compared to the third quarter of 2024. Net cash provided by operating activities in the first nine months of 2025 was $83.7 million, an improvement of $33.2 million compared to the same period in 2024.
Page 2
Adjusted EBITDA for the third quarter of 2025 was $39.7 million, an improvement of 45% compared to the third quarter of 2024, representing 30.1% of revenue compared to 23.6% of revenue in the same period of 2024. 2025 Financial Outlook The company is raising full-year 2025 testing revenue guidance to $484 million to $487 million, or 16% year-over-year growth, from prior guidance of $477 million to $483 million. Adjusting for the impact of the paused Envisia test, the guidance implies 17% to 18% year-over-year testing revenue growth. The company is also raising full-year 2025 total revenue guidance to $506 million to $510 million, or 14% year-over-year growth, from prior guidance of $496 million to $504 million. Additionally, the company is raising guidance for 2025 adjusted EBITDA as a percentage of revenue to over 25% from the 23.5% prior guidance. The company is unable to provide a quantitative reconciliation of expected adjusted EBITDA as a percentage of revenue to the most directly comparable forward-looking GAAP measure without unreasonable effort, because of the inherent difficulty in accurately forecasting the occurrence and financial impact of the various adjusting items necessary for such reconciliations that have not yet occurred, that are dependent on various factors, are out of the company’s control, or that cannot be reasonably predicted. Such adjustments include, but are not limited to, acquisition-related expenses, and other adjustments. Any associated estimate of these items and their impact on GAAP performance for the guidance period could vary materially. For more information on the non-GAAP financial measures, please refer to the section titled “Note Regarding Use of Non-GAAP Financial Measures” at the end of this press release. Conference Call and Webcast Details Veracyte will host a conference call and webcast today at 4:30 p.m. Eastern Time to discuss the company's financial results and provide a general business update. The conference call will be webcast live from the company’s website and will be available via the following link: https://edge.media- server.com/mmc/p/kcexjtb4. The webcast should be accessed 10 minutes prior to the conference call start time. A replay of the webcast will be available for one year following the conclusion of the live broadcast and will be accessible on the company’s website at https://investor.veracyte.com /events-presentations. The conference call dial-in can be accessed by registering via the following link: https://register-conf.media-server.com/register /BIdae4aec5409542e898e39e3944b8a094. About Veracyte Veracyte (Nasdaq: VCYT) is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our Veracyte Diagnostics Platform delivers high-performing cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and a powerful evidence-generation engine, which ultimately drives durable reimbursement and guideline inclusion for our tests, along with new insights to support continued innovation and pipeline development. For more information, please visit www.veracyte.com or follow us on LinkedIn or X (Twitter). Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements, including, but not limited to our statements related to our plans, objectives, and expectations (financial and otherwise), including with respect to our 2025 financial and operating results; and our intentions with respect to our tests and products, including upcoming product launches. Forward-looking statements can be identified by words such as: “appears,” “anticipate,” “intend,” “plan,” “expect,” “believe,” “should,” “may,” “could,” “would,” “will,” “enable,” “positioned,” “offers,” “designed,” “ultimately,” “strategic,” “outlook,” “guidance,” and similar references to future periods. Actual results may differ materially from those projected or suggested in any forward-looking statements. These statements involve risks and uncertainties, which could cause actual results to differ materially from our predictions, and include, but are not limited to: our ability to launch, commercialize and receive reimbursement for our products; our ability to execute on our business strategies relating to the C2i Genomics acquisition, integration of the business and the realization of expected benefits and synergies; our ability to demonstrate the validity and utility of our genomic tests and biopharma and other offerings; our ability to continue executing on our business plan; our ability to continue to scale our global operations and enhance our internal control environment; the impact of the war in Ukraine and other regional conflicts on European economies; the impact of foreign currency fluctuations, volatile interest rates, inflation, the impact of legislation and policies enacted by the current U.S. administration; turmoil in the global banking and finance system; the ongoing conflict in the Middle East; and the performance and utility of our tests in the clinical environment. Additional factors that may impact these forward-looking statements can be found under the caption “Risk Factors” in our Annual Report on Form 10-K filed on February 28, 2025, as well as in other documents that we may file from time to time with the Securities and Exchange Commission. Copies of these documents, when available, may be found in the Investors section of our website at investor.veracyte.com. These forward-looking statements speak only as of the date hereof and, except as required by law, we specifically disclaim any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise. Note Regarding Use of Non-GAAP Financial Measures In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), this press release and the accompanying tables contain, and reference certain non‐GAAP results including non-GAAP gross margin, non-GAAP operating expenses, adjusted EBITDA, adjusted EBITDA as a percentage of revenue (also referred to as adjusted EBITDA margin), non-GAAP net income, and non-GAAP earnings per share (EPS) and non-GAAP weighted average shares outstanding. These non-GAAP financial measures are not meant to be considered superior to or a substitute for financial measures calculated in accordance with GAAP, and investors are cautioned that there are material limitations associated with the use of non-GAAP financial measures as an analytical tool. We use non-GAAP financial measures to internally evaluate and analyze financial results. We believe these non-GAAP financial measures provide investors with useful supplemental information about the financial performance of our business, enable comparison of financial results between periods where certain items may vary independent of business performance, and enable comparison of our financial results with other public companies, many of which present similar non-GAAP financial measures. However, the non-GAAP financial measures we present may be different from those used by other companies, including similarly titled measures. We compute these non-GAAP measures by adjusting the applicable GAAP measure to remove the impact of certain recurring and non-recurring charges and gains and to adjust for the impact of income tax items related to such adjustments to our GAAP financial statements. In particular, we exclude amortization of acquired intangible assets, acquisition-related expenses relating to our acquisitions of Decipher Biosciences, HalioDx and C2i Genomics, impairment charges associated with the nCounter license and other biopharmaceutical services related to HalioDx intangible assets, all stock-based compensation and certain costs related to restructuring from all of our non-GAAP financial measures as well as depreciation and income tax items from our adjusted EBITDA and adjusted EBITDA as a percentage of revenue. Beginning in the second quarter of 2024, we changed our non-GAAP policy to exclude all stock-based compensation to align with our peers and we have also excluded all stock-based compensation from our
Page 3
prior period non-GAAP financial measures. Management has excluded the effects of these items in non-GAAP financial measures to help investors gain a better understanding of the core operating results and future prospects of the company, consistent with how management measures and forecasts the company’s performance, especially when comparing such results to previous periods or forecasts. The company encourages investors to carefully consider its results under GAAP, together with its supplemental non‐GAAP information and the reconciliation between these presentations. See “Reconciliation of U.S. GAAP to Non-GAAP Financial Measures” for a reconciliation of each non-GAAP measure presented to the comparable GAAP financial measure. VERACYTE, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (In thousands, except share and per share amounts) Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024 Revenue: Testing revenue $ 127,756 $ 109,536 $ 357,328 $ 306,809 Product revenue 3,301 3,188 10,479 10,631 Biopharmaceutical and other revenue 815 3,136 8,702 9,692 Total revenue 131,872 115,860 376,509 327,132 Cost of revenue: (1) Cost of testing revenue 33,777 29,029 94,444 82,928 Cost of product revenue 3,015 1,792 6,186 6,310 Cost of biopharmaceutical and other revenue 1,091 3,112 7,361 9,762 Intangible asset amortization - cost of revenue 2,707 2,917 7,959 8,741 Total cost of revenue 40,590 36,850 115,950 107,741 Gross profit 91,282 79,010 260,559 219,391 Operating expenses: (1) Research and development 15,981 17,574 49,965 50,004 Selling and marketing 24,455 22,612 74,225 70,610 General and administrative 27,278 25,742 93,417 83,697 Impairment of assets — 185 20,505 614 Intangible asset amortization - operating expenses 622 880 1,865 2,499 Total operating expenses 68,336 66,993 239,977 207,424 Income from operations 22,946 12,017 20,582 11,967 Other income (loss), net (4,057) 4,831 6,985 10,334 Income before income taxes 18,889 16,848 27,567 22,301 Income tax (benefit) provision (248) 1,693 2,363 3,276 Net income $ 19,137 $ 15,155 $ 25,204 $ 19,025 Earnings per share: Basic $ 0.24 $ 0.20 $ 0.32 $ 0.25 Diluted $ 0.24 $ 0.19 $ 0.32 $ 0.25 Shares used to compute earnings per common share: Basic 78,725,139 77,013,831 78,384,184 76,107,302 Diluted 79,691,703 78,464,654 79,946,386 77,339,897 1. Cost of revenue, research and development, sales and marketing and general and administrative expenses include the following stock-based compensation related expenses: Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024 Cost of revenue $ 540 $ 587 $ 1,668 $ 1,678 Research and development 1,949 1,957 6,023 5,615 Selling and marketing 2,102 1,790 6,258 5,025 General and administrative 6,166 4,413 18,751 14,302 Total stock-based compensation expense $ 10,757 $ 8,747 $ 32,700 $ 26,620 VERACYTE, INC. CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (LOSS) (Unaudited) (In thousands)
Page 4
Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024 Net income $ 19,137 $ 15,155 $ 25,204 $ 19,025 Other comprehensive income (loss): Change in currency translation adjustments (4,556) 9,328 19,575 2,736 Release of accumulated translation adjustment 8,295 — 8,295 — Other comprehensive income 3,739 9,328 27,870 2,736 Net comprehensive income $ 22,876 $ 24,483 $ 53,074 $ 21,761 VERACYTE, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands) September 30, December 31, 2025 2024 (Unaudited) (See Note 1) Assets Current assets: Cash and cash equivalents $ 315,573 $ 239,087 Short-term investments 50,855 50,354 Accounts receivable 47,826 46,525 Supplies and inventory 20,327 21,750 Prepaid expenses and other current assets 14,643 14,551 Total current assets 449,224 372,267 Property, plant and equipment, net 18,900 22,953 Right-of-use assets, operating leases 37,301 48,189 Intangible assets, net 92,477 102,301 Goodwill 767,154 745,800 Restricted cash 1,637 1,544 Other assets 1,094 6,981 Total assets $ 1,367,787 $ 1,300,035 Liabilities and Stockholders’ Equity Current liabilities: Accounts payable $ 5,509 $ 8,634 Accrued liabilities 48,373 43,826 Current portion of deferred revenue 417 1,673 Current portion of acquisition-related contingent consideration 13,571 16,981 Current portion of operating lease liabilities 4,282 7,500 Current portion of other liabilities — 19 Total current liabilities 72,152 78,633 Deferred tax liabilities 1,214 1,227 Acquisition-related contingent consideration, net of current portion 583 561 Operating lease liabilities, net of current portion 36,171 43,237 Other liabilities — 411 Total liabilities 110,120 124,069 Total stockholders’ equity 1,257,667 1,175,966 Total liabilities and stockholders’ equity $ 1,367,787 $ 1,300,035 1. The condensed consolidated balance sheet at December 31, 2024 has been derived from the audited financial statements at that date included in the company's Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission on February 28, 2025. VERACYTE, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (In thousands) Nine Months Ended September 30, 2025 2024 Operating activities Net income $ 25,204 $ 19,025 Adjustments to reconcile net income to net cash provided by operating activities:
Page 5
Depreciation and amortization 16,117 17,206 Loss on disposal of property, plant and equipment 15 131 Stock-based compensation 32,700 26,620 Deferred income taxes (13) 10 Noncash lease expense 2,289 3,628 Revaluation of acquisition-related contingent consideration (2,713) 1,242 Effect of foreign currency on operations (3,845) (785) Amortization of discount on short-term investments (2,619) — Impairment loss 20,505 614 Non-cash loss on deconsolidation of subsidiary 3,863 — Changes in operating assets and liabilities: Accounts receivable (3,858) (8,396) Supplies and inventory (2,642) (4,175) Prepaid expenses and other current assets (6,416) 149 Other assets 331 (1,710) Operating lease liabilities (1,681) (3,929) Accounts payable (547) (2,950) Accrued liabilities and deferred revenue 7,034 3,892 Net cash provided by operating activities 83,724 50,572 Investing activities Acquisition of C2i, net of cash acquired — 5,012 Purchase of short-term investments (99,998) — Proceeds from maturity of short-term investments 102,116 — Purchases of property, plant and equipment (5,897) (7,146) Net cash used in investing activities (3,779) (2,134) Financing activities Payment of taxes on vested restricted stock units (14,645) (7,315) Proceeds from the exercise of common stock options and employee stock purchases 10,572 16,729 Net cash (used in) provided by financing activities (4,073) 9,414 Increase in cash, cash equivalents and restricted cash 75,872 57,852 Effect of foreign currency on cash, cash equivalents and restricted cash 707 (23) Net increase in cash, cash equivalents and restricted cash 76,579 57,829 Cash, cash equivalents and restricted cash at beginning of period 240,631 217,330 Cash, cash equivalents and restricted cash at end of period $ 317,210 $ 275,159 CASH, CASH EQUIVALENTS AND RESTRICTED CASH (Unaudited) (In thousands) September 30, December 31, 2025 2024 Cash and cash equivalents $ 315,573 $ 239,087 Restricted cash 1,637 1,544 Total cash, cash equivalents and restricted cash $ 317,210 $ 240,631 VERACYTE, INC. RECONCILIATION OF U.S. GAAP to NON-GAAP FINANCIAL MEASURES (Unaudited) (In thousands) Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024 Reconciliation of Non-GAAP Cost of Revenue: GAAP cost of testing revenue $ 33,777 $ 29,029 $ 94,444 $ 82,928 Stock-based compensation expense (555) (524) (1,543) (1,411) Acquisition related expenses (1) — — — (60) Other adjustments (2) — — — (6) Non-GAAP cost of testing revenue $ 33,222 $ 28,505 $ 92,901 $ 81,451 GAAP cost of product revenue 3,015 1,792 6,186 6,310 Stock-based compensation expense — (1) (2) (3)
Page 6
Acquisition related expenses (1) — — — — Other adjustments (2) (1,418) — (1,450) — Non-GAAP cost of product revenue $ 1,597 $ 1,791 $ 4,734 $ 6,307 GAAP cost of biopharmaceutical and other revenue 1,091 3,112 7,361 9,762 Stock-based compensation expense 15 (62) (123) (264) Acquisition related expenses (1) — — — — Other adjustments (2) — — — — Non-GAAP cost of biopharmaceutical and other revenue $ 1,106 $ 3,050 $ 7,238 $ 9,498 Reconciliation of Non-GAAP Gross Margin: GAAP Gross Profit $ 91,282 $ 79,010 $ 260,559 $ 219,391 GAAP Gross Margin 69.2% 68.2% 69.2% 67.1% Amortization of intangible assets 2,707 2,917 7,959 8,741 Stock-based compensation expense 540 587 1,668 1,678 Acquisition related expenses (1) — — — 60 Other adjustments (2) 1,418 — 1,450 6 Non-GAAP Gross Profit $ 95,947 $ 82,514 $ 271,636 $ 229,876 Non-GAAP Gross Margin 72.8% 71.2% 72.1% 70.3% 1. Includes transaction-related expenses. For the nine months ended September 30, 2024, adjustments consist primarily of transaction-related expenses associated with the acquisition of C2i Genomics. 2. For the three months ended September 30, 2025, and the nine months ended September 30, 2025, adjustments include expenses related to the restructuring and liquidation proceedings of Veracyte SAS. For the nine months ended September 30, 2024, adjustments include expenses related to restructuring cost associated with portfolio prioritization. VERACYTE, INC. RECONCILIATION OF U.S. GAAP to NON-GAAP FINANCIAL MEASURES (Unaudited) (In thousands) Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024 Reconciliation of Non-GAAP Operating Expenses: GAAP research and development $ 15,981 $ 17,574 $ 49,965 $ 50,004 Stock-based compensation expense (1,949) (1,957) (6,023) (5,615) Acquisition related expenses (1) — 459 — 62 Other adjustments (2) — 5 — (271) Non-GAAP research and development $ 14,032 $ 16,081 $ 43,942 $ 44,180 GAAP sales and marketing $ 24,455 $ 22,612 $ 74,225 $ 70,610 Stock-based compensation expense (2,102) (1,790) (6,258) (5,025) Acquisition related expenses (1) — — — (124) Other adjustments (2) — 7 — (1,087) Non-GAAP sales and marketing $ 22,353 $ 20,829 $ 67,967 $ 64,374 GAAP general and administrative $ 27,278 $ 25,742 $ 93,417 $ 83,697 Stock-based compensation expense (6,166) (4,413) (18,751) (14,302) Acquisition related expenses (1) (166) (349) (593) (4,934) Other adjustments (2) 1,308 (248) (6,530) (3,368) Non-GAAP general and administrative $ 22,254 $ 20,732 $ 67,543 $ 61,093 GAAP total operating expenses $ 68,336 $ 66,993 $ 239,977 $ 207,424 Amortization of intangible assets (622) (880) (1,865) (2,499) Stock-based compensation expense (10,217) (8,160) (31,032) (24,942) Acquisition related expenses (1) (166) (75) (593) (5,610) Other adjustments (2) 1,308 (236) (27,035) (4,726) Non-GAAP total operating expenses $ 58,639 $ 57,642 $ 179,452 $ 169,647 1. Includes transaction-related expenses as well as post-combination compensation expenses. For the three months ended September 30, 2025, adjustments consist primarily of transaction-related expenses associated with contingent consideration related to the NanoString Technologies, Inc. ("NanoString") transaction and contingent consideration associated with the C2i Genomics Ltd ("C2i Genomics") acquisition. For the three months ended September 30, 2024, adjustments consist primarily of transaction-related expenses associated with the acquisition of C2i Genomics
Page 7
($0.1 million). For the nine months ended September 30, 2025, adjustments consist primarily of transaction-related expenses associated with the acquisition of C2i Genomics ($1.6 million) partially offset by NanoString contingent consideration ($1.0 million). For the nine months ended September 30, 2024, adjustments consist of transaction-related expenses associated with the acquisition of C2i Genomics. 2. For the three months ended September 30, 2025, adjustments primarily include a vendor legal settlement ($2.8 million) partially offset by expenses related to the restructuring and liquidation proceedings of Veracyte SAS ($1.0 million) and other legal proceedings ($0.5 million). For the three months ended September 30, 2024, adjustments primarily include expense related to restructuring costs ($0.2 million). For the nine months ended September 30, 2025, adjustments include additional expenses related to Veracyte SAS impairment loss ($20.5 million) and related to the restructuring and liquidation proceedings of Veracyte SAS ($8.0 million), partially offset by adjustments related to restructuring costs ($0.1 million). For the nine months ended September 30, 2024, adjustments primarily include expense related to restructuring costs associated with a reduction in our Biopharmaceutical and Other segment ($3.1 million) and expense related to restructuring costs associated with portfolio prioritization including the reduction in Envisia commercial support ($1.6 million). VERACYTE, INC. RECONCILIATION OF U.S. GAAP to NON-GAAP FINANCIAL MEASURES (Unaudited) (In thousands) Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024 Reconciliation of Adjusted EBITDA: GAAP Net Income (Loss) $ 19,137 $ 15,155 $ 25,204 $ 19,025 GAAP Net Income (Loss) as a % of Revenue 14.5% 13.1% 6.7% 5.8% Amortization of intangible assets 3,329 3,797 9,824 11,240 Depreciation expense 1,938 2,081 6,293 5,966 Stock-based compensation expense 10,757 8,747 32,700 26,620 Acquisition related expenses (1) 166 75 593 5,670 Other expense (income), net (2) (3,484) (3,366) (9,630) (9,679) Other adjustments (3) 8,138 (853) 32,876 3,643 Income tax expense (benefit) (248) 1,693 2,363 3,276 Adjusted EBITDA $ 39,733 $ 27,329 $ 100,223 $ 65,761 Adjusted EBITDA as a % of Revenue 30.1% 23.6% 26.6% 20.1% Reconciliation of Non-GAAP Net Income (Loss) GAAP Net Income (Loss) $ 19,137 $ 15,155 $ 25,204 $ 19,025 Amortization of intangible assets 3,329 3,797 9,824 11,240 Stock-based compensation expense 10,757 8,747 32,700 26,620 Acquisition related expenses (1) 166 75 593 5,670 Other adjustments (3) 8,138 (853) 32,876 3,643 Tax adjustments (4) (565) (933) (807) (2,179) Non-GAAP Net Income $ 40,962 $ 25,988 $ 100,390 $ 64,019 Reconciliation of Non-GAAP Earnings per Share Diluted earnings per share, GAAP $ 0.24 $ 0.19 $ 0.32 $ 0.25 Amortization of intangible assets 0.04 0.05 0.12 0.15 Stock-based compensation expense 0.13 0.11 0.41 0.34 Acquisition related expenses (1) — — 0.01 0.07 Other adjustments (3) 0.10 (0.01) 0.41 0.05 Tax adjustments (4) (0.01) (0.01) (0.01) (0.03) Rounding and impact of dilutive shares 0.01 — — — Diluted earnings per share, non-GAAP $ 0.51 $ 0.33 $ 1.26 $ 0.83 Weighted average shares outstanding used in computing diluted earnings per share Diluted, GAAP 79,691,703 78,464,654 79,946,386 77,339,897 Dilutive effect of equity awards (5) — — — — Diluted, non-GAAP 79,691,703 78,464,654 79,946,386 77,339,897 1. Includes transaction-related expenses as well as post-combination compensation expenses. For the three months ended September 30, 2025, adjustments consist primarily of transaction-related expenses associated with contingent consideration related to NanoString and contingent consideration associated with the acquisition of C2i Genomics. For the three months ended September 30, 2024, adjustments consist primarily of transaction related expenses associated with the acquisition of C2i Genomics ($0.1 million). For the nine months ended September 30, 2025, adjustments consist primarily of transaction-related expenses associated with the acquisition of C2i Genomics ($1.6 million) partially offset by NanoString contingent consideration ($1.0 million). For the nine months ended September 30, 2024, adjustments consist of transaction-related expenses associated with the acquisition of C2i Genomics. 2. Includes interest income and income related to research tax credits.
Page 8
3. For the three months ended September 30, 2025, adjustments primarily include expenses related to the exclusion of unrealized loss related to Veracyte SAS deconsolidation ($6.7 million), the exclusion of unrealized loss associated with foreign exchange impact on stock-based compensation and intercompany loans ($1.3 million), the restructuring and liquidation proceedings of Veracyte SAS ($2.4 million), and other legal proceedings ($0.5 million), partially offset by vendor legal settlement ($2.8 million). For the three months ended September 30, 2024, adjustments include the exclusion of unrealized gains associated with foreign exchange impacts on stock-based compensation and intercompany loans ($1.1 million) partially offset by expense related to restructuring costs ($0.2 million). For the nine months ended September 30, 2025 adjustments include additional expenses related to Veracyte SAS impairment loss ($20.5 million) and Veracyte SAS investment review ($8.0 million), partially offset by adjustments related to restructuring costs ($0.1 million) and additional exclusion of unrealized gains associated with foreign exchange impacts on stock-based compensation and intercompany loans ($3.6 million). For the nine months ended September 30, 2024, adjustments primarily include expense related to restructuring costs associated with a reduction in our Biopharmaceutical and Other Segment ($3.1 million) and expense related to restructuring costs associated with portfolio prioritization including the reduction in Envisia commercial support ($1.6 million), partially offset by the exclusion of unrealized gains associated with foreign exchange impacts on stock-based compensation and intercompany loans ($1.1 million). 4. Incremental non-GAAP tax expense reflects the tax impact of the non-GAAP adjustments listed. 5. In those periods in which GAAP net (loss) income is negative and non-GAAP net (loss) income is positive, non-GAAP diluted weighted average shares outstanding includes potentially dilutive common shares from equity awards as determined using the treasury stock method. View source version on businesswire.com: https://www.businesswire.com/news/home/20251104771700/en/ Investors: Shayla Gorman investors@veracyte.com 619-393-1545 Media: Karen Possemato media@veracyte.com Source: Veracyte, Inc.